Plasmepsin 4 from Plasmodium falciparum and orthologs from Plasmodium malariae, Plasmodium ovale and Plasmodium vivax have been expressed in recombinant form, and properties of the active site of each enzyme characterized by kinetic analysis. A panel of chromogenic peptide substrates systematically substituted at the P3, P2, P2' and P3' positions was used to estimate enzyme/ligand interactions in the corresponding enzyme subsites based upon kinetic data. The kinetic parameters kcat, Km and kcat/Km were measured to identify optimal substrates for each enzyme and also sequences that were readily cleaved by the plasmepsins but poorly by host aspartic peptidases. Computer generated models were utilized to compare enzyme structures and interpret kinetic results. The orthologous plasmepsins share highly similar subsite specificities. In the S3 and S2 subsites, the plasmepsin 4 orthologs all preferred hydrophobic amino acid residues, Phe or Ile, but rejected charged residues such as Lys or Asp. In S2' and S3' subsites, these plasmepsins tolerated both hydrophobic and hydrophilic residues. Subsite specificities of the plasmepsin 4 family of orthologs are similar to those of human cathepsins D and E, except in S3' where the plasmepsins accept substrates containing Ser significantly better than either of these human aspartic proteases. Peptidomimetic methyleneamino reduced-peptide inhibitors, which have inhibition constants in the picomolar range, were prepared for each plasmepsin 4 ortholog based upon substrate preferences. A peptidomimetic inhibitor designed for plasmepsin 4 from P. falciparum having Ser in P3' had the lowest Ki of the series of inhibitors prepared, but did not significantly improve the selectivity of the inhibitor for plasmepsin 4 versus human cathepsin D.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molbiopara.2004.01.010DOI Listing

Publication Analysis

Top Keywords

plasmepsin plasmodium
8
subsite specificities
8
plasmepsin
7
plasmodium
5
recombinant expression
4
expression enzymatic
4
enzymatic subsite
4
subsite characterization
4
characterization plasmepsin
4
plasmodium species
4

Similar Publications

Low prevalence of copy number variation in pfmdr1 and pfpm2 in Plasmodium falciparum isolates from southern Angola.

Malar J

January 2025

Global Health and Tropical Medicine, GHTM, Associate Laboratory in Translation and Innovation Towards Global Health, LA-REAL, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, UNL, Rua da Junqueira 100, 1349-008, Lisbon, Portugal.

Background: Malaria is the parasitic disease with the highest global morbidity and mortality. According to estimates from the World Health Organization (WHO), there were around 249 million cases in 2022, with 3.4% occurring in Angola.

View Article and Find Full Text PDF

The antimalarial activity of transdermal N-89 mediated by inhibiting ERC gene expression in P. Berghei-infected mice.

Parasitol Int

December 2024

Division of International Infectious Diseases Control, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8530, Japan. Electronic address:

Through studies of new antimalarial drugs, we identified 1,2,6,7-tetraoxaspiro[7.11]nonadecane (N-89) as a potential drug candidate. Here, we analyzed the antimalarial action of a transdermal formulation (td) of N-89, designed for easy use by children, using Plasmodium berghei-infected mice as a model for malaria patients.

View Article and Find Full Text PDF

Oxidative stress is a pivotal factor in the pathogenesis of malaria, contributing to the development of conditions such as anemia, respiratory complications, and cerebral malaria. To counteract oxidative damage, we evaluated the effects of vitamin E (α-TOH) and d-α-tocopherol polyethylene glycol 1000 succinate (TPGS) supplementation on parasitemia progression, mortality rate, and blood-brain barrier (BBB) permeability in Plasmodium berghei ANKA-infected mice. The mice were divided into four groups: a control group (untreated and uninfected), an infected group (Pb), a TPGS + Pb group, and an α-TOH + Pb group.

View Article and Find Full Text PDF

Molecular insights into the aspartate protease Plasmepsin II activity inhibition by fluoroquinolones: A pathway to antimalarial drug development.

Int J Biol Macromol

January 2025

UM-DAE Centre for Excellence in Basic Sciences, University of Mumbai, Vidyanagri Campus, Kalina, Mumbai 400098, India. Electronic address:

Article Synopsis
  • Plasmepsin II (PlmII) is an important enzyme in Plasmodium falciparum that helps in breaking down hemoglobin, making it a key target for new antimalarial drugs.
  • Research successfully produced and activated Pro-plasmepsin II, confirming its functionality through various enzyme studies, and identified that norfloxacin and ciprofloxacin can effectively inhibit this enzyme, unlike sparfloxacin.
  • The study suggests repurposing these fluoroquinolone antibiotics for malaria treatment, highlighting their mechanism of action at the enzyme’s active site, which could lead to new therapeutic options against malaria.
View Article and Find Full Text PDF

Advances in protease inhibition-based chemotherapy: A decade of insights from Malaria research.

Adv Parasitol

October 2024

Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic; Faculty of Science, University of South Bohemia, Ceske Budejovice, Czech Republic.

Article Synopsis
  • Recent research on the parasite Plasmodium falciparum has advanced our understanding of protease isoenzymes, revealing their unique roles and biochemical features.
  • *The findings have led to new chemotherapy options that utilize low molecular weight inhibitors to target specific molecular sites within the parasite.
  • *Additionally, advancements in proteasome inhibition and research on vital metalloproteases are paving the way for the potential treatment and study of other lesser-known parasitic diseases.*
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!